IONS News and Press, Ionis Pharmaceuticals Inc.

2024-06-27 11:30:07 ET Wells Fargo analyst issues BUY recommendation for IONS on June 27, 2024 09:00AM ET. The previous analyst recommendation was Buy. IONS was trading at $47.5097 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current a...

2024-06-27 11:30:06 ET Oppenheimer analyst issues UNDERPERFORM recommendation for IONS on June 27, 2024 09:00AM ET. The previous analyst recommendation was Underperform. IONS was trading at $47.5097 at issue of the analyst recommendation. The overall analyst consensus : ...

2024-06-25 15:39:29 ET More on Ionis Pharmaceuticals Ionis: Tough Run For Share Price Belies Multiple Reasons For Optimism Ionis Pharmaceuticals, Inc. (IONS) Q1 2024 Earnings Call Transcript ALS therapy market seen increasing to nearly $1.3B by 2029 Ionis her...

Ionis announces olezarsen FCS New Drug Application accepted for Priority Review and enrollment in Phase 3 sHTG program completed PR Newswire – Olezarsen PDUFA date set for December 19, 2024 for treatment of familial chylomicronemia syndrome – – ...

2024-06-24 11:37:31 ET Summary HELIOS-B Phase III study of Amvuttra in patients with ATTR-CM succeeded across all metrics, showing significant benefits in both the combined study population and monotherapy groups. Amvuttra showed strong efficacy in reducing all-cause mortality and...

2024-06-24 08:49:49 ET More on Alnylam Pharmaceuticals Upcoming Pivotal HELIOS-B Data Looms Large For Alnylam's Valuation Alnylam Pharmaceuticals, Inc. (ALNY) Q1 2024 Earnings Call Transcript Alnylam Pharmaceuticals, Inc. 2024 Q1 - Results - Earnings Call Presentatio...

2024-06-24 01:43:14 ET Summary Astria Therapeutics stock has fallen 40% since early 2023, but promising early data for its candidate STAR-0215 in treating HAE is helping drive analyst Buy ratings. ATXS stock has a compound called STAR-0310 in development for an immune disorder, wi...

Ionis announces expanded licensing agreement with Otsuka in Asia Pacific for investigational medicine donidalorsen in hereditary angioedema PR Newswire Otsuka will be responsible for commercialization efforts for donidalorsen across both Asia Pacific and Europe Ion...

Ionis to present at TD Cowen Genetic Medicines & RNA Summit Ionis to present at TD Cowen Genetic Medicines & RNA Summit PR Newswire CARLSBAD, Calif. , June 17, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that manage...

2024-06-15 15:37:28 ET The market for medicines to treat amyotrophic lateral sclerosis (ALS) in major markets is projected to more than surge to $1.28B in 2029 from $317M in 2019, representing a CAGR of 15%.... Read the full article on Seeking Alpha For further details see: ...